Comparison of Regeneron Pharmaceuticals Inc. (REGN) and Iterum Therapeutics plc (NASDAQ:ITRM)

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Iterum Therapeutics plc (NASDAQ:ITRM), both competing one another are Biotechnology companies. We will compare their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Regeneron Pharmaceuticals Inc. 6.37B 6.90 1.80B 18.46 20.46
Iterum Therapeutics plc N/A 90.25 61.92M -4.59 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Regeneron Pharmaceuticals Inc. and Iterum Therapeutics plc.

Profitability

Table 2 provides us the return on assets, return on equity and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Regeneron Pharmaceuticals Inc. 28.26% 25.9% 18.5%
Iterum Therapeutics plc 0.00% 0% 0%

Liquidity

Regeneron Pharmaceuticals Inc. has a Current Ratio of 4 and a Quick Ratio of 3.6. Competitively, Iterum Therapeutics plc’s Current Ratio is 14 and has 14 Quick Ratio. Iterum Therapeutics plc’s better ability to pay short and long-term obligations than Regeneron Pharmaceuticals Inc.

Analyst Recommendations

Ratings and Recommendations for Regeneron Pharmaceuticals Inc. and Iterum Therapeutics plc can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Regeneron Pharmaceuticals Inc. 0 3 2 2.40
Iterum Therapeutics plc 0 0 0 0.00

Regeneron Pharmaceuticals Inc.’s upside potential currently stands at 1.44% and an $412.33 average price target.

Institutional and Insider Ownership

Institutional investors held 73.7% of Regeneron Pharmaceuticals Inc. shares and 71.4% of Iterum Therapeutics plc shares. About 0.4% of Regeneron Pharmaceuticals Inc.’s share are held by insiders. Competitively, Iterum Therapeutics plc has 3.1% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Regeneron Pharmaceuticals Inc. 3.27% 3.66% -4.42% 21.04% 1.07% 0.43%
Iterum Therapeutics plc 23.45% 28.58% -7.96% -35.5% 0% -39.76%

For the past year Regeneron Pharmaceuticals Inc. has 0.43% stronger performance while Iterum Therapeutics plc has -39.76% weaker performance.

Summary

On 9 of the 11 factors Regeneron Pharmaceuticals Inc. beats Iterum Therapeutics plc.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.